Biocartis Group NV (BCART.BR)
- GlobeNewswire
Press release Biocartis Group NV: Results of the Annual Shareholders’ Meeting held on 13 May 2022
PRESS RELEASE: 13 May 2022, 17:40 CEST Results of the Annual Shareholders’ Meeting held on 13 May 2022 Mechelen, Belgium, 13 May 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), held its annual shareholders' meeting today. The shareholders approved all items on the agenda. All documents relating to the annual shareholders’ meeting can be consulted on the website of the Company. --- END --- More information: Renate D
- GlobeNewswire
Press release Biocartis Group NV: New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods
PRESS RELEASE: 4 May 2022, 07:00 CEST New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods Therapeutically actionable gene fusions drive approximately 10% of non-small-cell lung cancers1Current molecular methods including Next Generation Sequencing (NGS) are complex with long turnaround timesStudy2 demonstrates the Idylla™ GeneFusion Assay (RUO3) enables more rapid screening
- GlobeNewswire
Press release Biocartis Group NV: Biocartis Announces Presentation of Three Idylla™ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
PRESS RELEASE: 25 April 2022, 07:00 CEST Biocartis Announces Presentation of Three Idylla™ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Mechelen, Belgium, 25 April 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that three Idylla™ study posters, of which two on the SeptiCyte® RAPID (developed in collaboration with Immunexpress) and one on the Idylla™ SARS
